Stay updated with breaking news from Regulatory Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE, Mass., Jan. 27, 2022Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM (aducanumab-avwa)
WESTON (dpa-AFX) - Biogen Inc. (BIIB), an American company focused on the therapies for the treatment of neurological diseases said it intends to seek re-examination of negative opinion adopted
Biogen to seek re-examination following CHMP negative opinion for aducanumabCAMBRIDGE, Mass., Dec. 17, 2021Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Committee for
Sage Therapeutics Inc. and Biogen Inc. released 12-month data showing zuranolone was generally well-tolerated among adults with major depressive disorder. A total of 199 patients received zuranolone 50 mg once per night for 2 weeks as their initial dose in the ongoing phase 3 open-label SHORELINE Study, with potential for 12 months of follow-up. The study is part of the LANDSCAPE clinical program
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or... | December 1, 2021